Iambic Therapeutics: Chief medical officer Josephson Neil received 216,900 shares

What happened Josephson Neil, chief medical officer, received 31,000 shares and 185,900 shares (reported as a derivative acquisition) on Oct 14, 2026. Both transactions were reported at $0.00 per share for a total reported value of $0.

Key details

• Transaction date(s) and price(s): Oct 14, 2026; both acquisitions reported at $0.00 per share.
• Shares owned after the transaction: not reported in the filing.
• Footnotes in the filing: F1 states the reported shares are restricted stock units (RSUs) that vest 25% on Sep 10, 2027 and the remainder in 12 equal quarterly installments beginning Dec 10, 2027. F2 states 25% of the shares subject to the option vest on Oct 14, 2027 and 1/48th vest monthly thereafter.
• Filing date and timeliness: the Form 4 was filed on Oct 16, 2026 for a transaction dated Oct 14, 2026; no late filing indicator was reported.

Why it may matter These entries were awards of restricted stock units and a reported derivative acquisition, not open-market purchases or sales. The filing does not show why the insider traded or why the company acted.